Expression of 15‑hydroxyprostaglandin dehydrogenase and cyclooxygenase‑2 in non‑small cell lung cancer: Correlations with angiogenesis and prognosis

Li,Ying; Li,Suli; Sun,Dan; Song,Linlin; Liu,Xinmin

doi:10.3892/ol.2014.2371

Expression of 15‑hydroxyprostaglandin dehydrogenase and cyclooxygenase‑2 in non‑small cell lung cancer: Correlations with angiogenesis and prognosis

Authors:
- Ying Li
- Suli Li
- Dan Sun
- Linlin Song
- Xinmin Liu
View Affiliations

Affiliations: Center of Gerontology and Geriatrics, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, National Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Geriatrics, Peking University First Hospital, Beijing 100034, P.R. China
Published online on: July 22, 2014 https://doi.org/10.3892/ol.2014.2371
Pages: 1589-1594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the function of 15‑hydroxyprostaglandin dehydrogenase (15‑PGDH) and cyclooxygenase‑2 (COX‑2) in angiogenesis and their association with the prognosis of non‑small cell lung cancer (NSCLC). Using immunohistochemical staining, the expression of 15‑PGDH and COX‑2, and the microvessel density (MVD) levels were evaluated in 35 NSCLC specimens. Paracancerous normal lung tissue was collected as control samples from six patients. The correlation of 15‑PGDH with COX‑2, clinicopathological characteristics, MVD and overall survival (OS) was studied. NSCLC tissues showed a significantly lower expression level of 15‑PGDH (P=0.009) and a significantly higher expression level of COX‑2 (P=0.004) compared with normal lung tissue. The expression level of 15‑PGDH was negatively correlated with MVD (P<0.001) and COX‑2 expression (P=0.032). A low expression level of 15‑PGDH, a high expression level of COX‑2 and high levels of MVD were significantly correlated with a shorter OS time (15‑PGDH, P<0.0001; COX‑2, P=0.038; MVD, P<0.0001). This study provided clinical evidence that a low expression level of 15‑PGDH is associated with a poor prognosis in NSCLC. Furthermore, it was shown that 15‑PGDH and COX‑2 reciprocally regulate cancer angiogenesis, which may affect the prognosis of patients with NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009.
2	Wang D and Dubois RN: Prostaglandins and cancer. Gut. 55:115–122. 2006.
3	Tai HH: Prostaglandin catabolic enzymes as tumor suppressors. Cancer Metastasis Rev. 30:409–417. 2011.
4	Na HK, Park JM, Lee HG, et al: 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem Pharmacol. 82:1352–1360. 2011.
5	Tai HH, Cho H, Tong M and Ding Y: NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des. 12:955–962. 2006.
6	Tatsuwaki H, Tanigawa T, Watanabe T, et al: Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci. 101:550–558. 2010.
7	Wolf I, O’Kelly J, Rubinek T, et al: 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 66:7818–7823. 2006.
8	Pham H, Chen M, Li A, et al: Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pancreas. 39:332–339. 2010.
9	Quidville V, Segond N, Lausson S, et al: 15-Hydroxyprostaglan- din-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat. 81:14–30. 2006.
10	Lou LH, Jing DD, Lai YX, et al: 15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma. World J Gastroenterol. 18:1028–1037. 2012.
11	Tseng-Rogenski S, Gee J, Ignatoski KW, et al: Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol. 176:1462–1468. 2010.
12	Huang G, Eisenberg R, Yan M, et al: 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res. 68:5040–5048. 2008.
13	Wakimoto N, Wolf I, Yin D, et al: Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res. 68:6978–6986. 2008.
14	Backlund MG, Mann JR, Holla VR, et al: Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res. 68:9331–9337. 2008.
15	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
16	Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: pp. 26–44. 2004
17	Gou HF, Chen XC, Zhu J, et al: Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 30:142011.
18	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991.
19	Ding Y, Tong M, Liu S, Moscow JA and Tai HH: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 26:65–72. 2005.
20	Backlund MG, Mann JR, Holla VR, et al: 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 280:3217–3223. 2005.
21	Lim SC, Cho H, Lee TB, et al: Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer. Yonsei Med J. 51:692–699. 2010.
22	Liu Z, Wang X, Lu Y, et al: Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis. 29:1219–1227. 2008.
23	Tennis MA, Vanscoyk M, Keith RL and Winn RA: The role of prostacyclin in lung cancer. Transl Res. 155:57–61. 2010.
24	Tong M, Ding Y and Tai HH: Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis. 27:2170–2179. 2006.
25	Krishnan AV, Swami S and Feldman D: Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol. 121:343–348. 2010.
26	Lim K, Han C, Xu L, et al: Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 68:553–560. 2008.
27	Lim K, Han C, Dai Y, Shen M and Wu T: Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther. 8:3046–3055. 2009.
28	Sahin M1, Sahin E and Gümüslü S: Cyclooxygenase-2 in cancer and angiogenesis. Angiology. 60:242–253. 2009.
29	Zhou D, Cheng SQ, Ji HF, et al: Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol. 136:1719–1727. 2010.
30	Qin LX and Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 130:497–513. 2004.
31	Gulubova M and Vlaykova T: Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 24:1265–1275. 2009.
32	Aurello P, Bellagamba R, Rossi Del Monte S, et al: Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg. 75:1183–1188. 2009.
33	Meert AP, Paesmans M, Martin B, et al: The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 87:694–701. 2002.
34	Luo H, Chen Z, Jin H, et al: Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer. J Exp Clin Cancer Res. 30:62011.
35	Huang SP, Wu MS, Shun CT, et al: Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci. 12:229–241. 2005.
36	Brecht K, Weigert A, Hu J, et al: Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J. 25:2408–2417. 2011.
37	Zhang B, Ma X, Li Z, et al: Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol. 139:797–807. 2013.